Adaptimmune

ADAP NASDAQ
3.750
+0.090
+2.46%
交易中 14:04 06/24 EDT
开盘
3.700
昨收
3.660
最高
3.750
最低
3.550
成交量
9.77万
成交均量(3M)
30.61万
52周最高
14.54
52周最低
3.200
换手率
0.09%
市值
3.93亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Adaptimmune ADAP股票价格,Adaptimmune股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
展开 >

最近浏览

名称
价格
涨跌幅